Guggenheim Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Guggenheim Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-39,097	Closed	-$289K	–	2024
2022 Q4	$289K	Sell	39,097 -3,931	-9%	-$38.3K	﹤0.01%	1682
2022 Q3	$425K	Sell	43,028 -8,567	-17%	-$90.5K	﹤0.01%	1545
2022 Q2	$563K	Buy	51,595 +2,793	+6%	+$28.9K	﹤0.01%	1527
2022 Q1	$552K	Buy	48,802 +6,582	+16%	+$86.5K	﹤0.01%	1653
2021 Q4	$662K	Sell	42,220 -11,759	-22%	-$205K	﹤0.01%	1550
2021 Q3	$925K	Buy	53,979 +31,692	+142%	+$555K	0.01%	1452
2021 Q2	$479K	Buy	+22,287	New	+$399K	﹤0.01%	1846
2014 Q4	–	Sell	-146,195	Closed	-$1.52M	–	3108
2014 Q3	$1.52M	Buy	146,195 +17,039	+13%	+$223K	﹤0.01%	1964
2014 Q2	$2.09M	Sell	129,156 -16,992	-12%	-$226K	0.01%	1785
2014 Q1	$2.38M	Sell	146,148 -12,026	-8%	-$171K	0.01%	1650
2013 Q4	$1.96M	Buy	+158,174	New	+$1.59M	0.01%	1810

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Guggenheim Capital's VNDA Position: Q1 2023 in Review

Guggenheim Capital sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 39,097 shares — an estimated $289K sold.

Guggenheim Capital first reported a position in VNDA in Q4 2013 and held it in 11 quarters. The position peaked at $2.38M in Q1 2014. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

Guggenheim Capital reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Guggenheim Capital sold 39,097 Vanda Pharmaceuticals shares in Q1 2023, an estimated $289K.
Guggenheim Capital first reported a position in Vanda Pharmaceuticals in Q4 2013 and held it in 11 quarters.
Guggenheim Capital's Vanda Pharmaceuticals position peaked at $2.38M in Q1 2014.
177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on Guggenheim Capital's 13F filing for Q1 2023, filed 11 May 2023.